← Back to all trials
Enrolling By Invitation
NCT07910422
Intradiscal Ozone/Oxygen Injection for Treatment of Contained Lumbar Disc Herniation
Conditions: Lumbar Disc Herniation
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 80
Sponsor: Beam Research, Inc.
Location: Beam Research Inc. Calgary Alberta
Summary
This study is retrospectively designed and aims to evaluate and summarize safety and performance data in eligible participants who have undergone Intradiscal ozone-oxygen injection for treatment of lumbar disc herniation with the Triojection® System in Canada under Special Access Program (SAP) between April 2022 and 31 March 2026 at one(1) participating site.
The primary objectives of the study are :
1. To evaluate the clinical success in eligible participants who have undergone intradiscal ozone-oxygen injection procedure with the Triojection® System for treatment of lumbar disc herniation.
2. To evaluate the safety in eligible participants who have undergone the procedure.
Retrospective data will be collected from existing medical records across three predefined periods:
* Baseline, defined as within 180 days prior to treatment (index procedure);
* Treatment, of variable duration, encompassing clinic admission, performance of the index procedure, post-procedure recovery, and discharge;
* Follow-up, of variable duration, including any follow-up visits performed after discharge as part of the standard course of medical care.
In addition, prospective data collection will be performed during a separate follow-up period of variable duration, consisting of follow-up visits conducted either remotely or in person to collect participant-reported outcomes including pain, function, work status, updated medical history, and medication use.
Eligibility Criteria
Inclusion Criteria:
* Participant is greater than or equal to 18 years of age;
* Participant has consented to and has undergone (attempted or completed) an intradiscal ozone-oxygen injection procedure with the Triojection® System for the treatment of lumbar disc herniation in Canada under an approved SAP request at the participating site between April 2022 and 31 March 2026;
* Participant is willing and able to provide written informed consent for retrospective data collection.
For participation in the prospective phase, the subject must additionally meet the following criteria:
\- Subject is willing and able to provide written informed consent for prospective data collection .
Exclusion Criteria:
As this study is intended to collect and report data on an all-comers basis representative of subjects encountered in routine clinical practice, no exclusion criteria have been defined.
Source: ClinicalTrials.gov (NCT07910422). StuddyBuddy aggregates publicly available trial information.